|Articles|February 28, 2023
Rare Disease Day: Updates on Friedreich Ataxia and Myotonic Muscular Dystrophy
Author(s)Marco Meglio
In recognition of Rare Disease Day, the NeurologyLive® team offered an extensive update on the state of care and treatment for a few rare neurological diseases, including Pompe disease, Rett syndrome, among others.
Advertisement
Since 2008, the medical field has designated February 28 as Rare Disease Day, a day to honor patients with all varieties of rare diseases. The international celebration has been practiced since 2009, when the National Organization for Rare Disorders offered its hand in spreading the day to others, helping to get advocacy groups in the United States—and eventually around the world—to observe the day.
NeurologyLive® proudly works in partnership with several rare disease advocacy organizations—including the ALS Association , Cure SMA , the Dravet Syndrome Foundation , the Lennox-Gastaut Syndrome Foundation , the TSC Alliance —aiming to increase awareness and inform clinicians of the latest advances for these rare and challenging-to-treat disorders. In observance of Rare Disease Day, our team spoke with experts on the current state of care and treatment for a few rare diseases implicated in neurological care, including Friedreich ataxia, myotonic muscular dystrophy, among others.
Switch between the slides below to learn more about the progress in Friedreich ataxia and myotonic muscular dystrophy. For more updates on progress in rare diseases, check out our updates on Pompe disease and Rett syndrome .
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
Expanding the Alzheimer Drug Development Pipeline
3
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
4
FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency
5